EVO - Evotec Se Profile, Share Price, Market Analysis, Charts, Fundamentals

Business Description

Evotec SE is a publicly-traded German biotechnology firm operating in the pharmaceutical and drug discovery industry. The company is headquartered in Hamburg, Germany, and has various locations and offices worldwide.

Evotec SE is primarily engaged in the development and discovery of drugs, which includes providing comprehensive solutions for the pharmaceutical industry. The company works with leading biopharmaceutical companies, academic institutions, and disease foundations, focusing on providing innovative solutions through collaborations and partnerships.

Founded in 1993, the company has over the years been focused on research and development, cutting-edge technologies and collaboration, drug discovery, and strategic partnerships. The company has built a reputation as a leading provider of high-value drug discovery services, particularly in the fields of neuroscience, oncology, and autoimmune diseases.

Their technology platform, called the "Evotec Operating System," integrates different lab technologies and data management capabilities, enabling high-throughput screening and drug identification. This platform has been instrumental in the company's success as it enables them to work collaboratively and efficiently in the drug discovery process.

Evotec SE's services range from target identification, validation, and optimization to drug screening, hit identification, and preclinical development. The company also offers customized solutions tailored for specific client needs and has several programs in clinical and pre-clinical stages of development.

Additionally, Evotec SE has an extensive drug development pipeline, which includes both proprietary programs as well as partnered programs. To date, the company has over 100 partners across the globe and an impressive portfolio of drug candidates.

In terms of financials, Evotec SE has been consistent in its revenue growth, with a revenue increase of 17% in 2020 compared to the previous year. As of mid-2021, the company reported a total of over 4,000 employees worldwide, showing significant growth and expansion over the years.

Overall, Evotec SE has established itself as a leading biotech company that leverages cutting-edge technologies, strategic partnerships, and collaboration in drug discovery and development. With a proven track record, a robust pipeline, and consistent growth, the company is well-positioned to continue making significant strides in the biotech industry.

Fundamental Analysis

Discovery Preclinical Development

65.66 %

of total Revenue

Just - Evotec Biologics

32.91 %

of total Revenue

Intereliminations

0.05 %

of total Revenue

Intereliminations Discovery Preclinical Development

-0.04 %

of total Revenue

Intereliminations Just - Evotec Biologics

-0.02 %

of total Revenue

USA

48.87 %

of total Revenue

USA Discovery Preclinical Development

36.64 %

of total Revenue

USA Just - Evotec Biologics

12.23 %

of total Revenue

Germany

2.86 %

of total Revenue

Germany Discovery Preclinical Development

2.86 %

of total Revenue

France

2.25 %

of total Revenue

France Discovery Preclinical Development

2.24 %

of total Revenue

France Just - Evotec Biologics

0.01 %

of total Revenue

United Kingdom

6.99 %

of total Revenue

United Kingdom Discovery Preclinical Development

6.99 %

of total Revenue

Switzerland

18.3 %

of total Revenue

Switzerland Discovery Preclinical Development

1.23 %

of total Revenue

Switzerland Just - Evotec Biologics

17.07 %

of total Revenue

Rest of the world

8.73 %

of total Revenue

Rest of the world Discovery Preclinical Development

8.66 %

of total Revenue

Rest of the world Just - Evotec Biologics

0.07 %

of total Revenue

At a point in time

20.82 %

of total Revenue

Over a period of time

77.75 %

of total Revenue

Fee for service and FTE-based research services

77.75 %

of total Revenue

Material re-charges to customers

4.05 %

of total Revenue

Milestone fees

1.22 %

of total Revenue

Licences

15.52 %

of total Revenue

Other fees

0.04 %

of total Revenue

Discovery Preclinical Development At a point in time

6.23 %

of total Revenue

Discovery Preclinical Development Over a period of time

59.43 %

of total Revenue

Discovery Preclinical Development Fee for service and FTE-based research services

59.43 %

of total Revenue

Discovery Preclinical Development Material re-charges to customers

4.05 %

of total Revenue

Discovery Preclinical Development Milestone fees

1.22 %

of total Revenue

Discovery Preclinical Development Licences

0.93 %

of total Revenue

Discovery Preclinical Development Other fees

0.04 %

of total Revenue

Just - Evotec Biologics At a point in time

14.59 %

of total Revenue

Just - Evotec Biologics Over a period of time

18.32 %

of total Revenue

Just - Evotec Biologics Fee for service and FTE-based research services

18.32 %

of total Revenue

Just - Evotec Biologics Licences

14.59 %

of total Revenue

Major customers

37.08 %

of total Revenue

Major customers Just - Evotec Biologics

19.44 %

of total Revenue

Major customers Discovery Preclinical Development

17.64 %

of total Revenue

Evotec Se Company Profile

Business Description

Fundamental Analysis